However, by optimizing the upstream production and downstream purification of AAV vector particles, biopharmaceutical companies can overcome these common manufacturing challenges. This webinar ...

When Robert Atchison and his colleagues at the University of Pittsburgh first stumbled across adeno-associated viruses (AAV) in 1965 ... for large-scale manufacturing. What’s more, it needed ...

There is a significant need for new drug manufacturing and analytical workflows that enable the scaleup and characterization of AAV and viral ... such as filters upstream in the production process ...